Form 4: Zeo ScientifiX Director Wendy Grey Receives 175,000 Share Grant

Zeo ScientifiX, Inc. director and 10% owner Wendy Grey was granted 175,000 restricted common shares under the company's 2021 Equity Incentive Plan.

Summary

• Wendy Grey, a director and 10% owner of Zeo ScientifiX, Inc. (ZEOX), was granted 175,000 shares of common stock.
• The shares were granted on January 14, 2026, under the company's 2021 Equity Incentive Plan.
• These shares are restricted and will vest 50% on the 8th month anniversary and the remaining 50% on the 12th month anniversary of the grant date.
• Following this transaction, Ms. Grey, through Greyt Ventures, LLC, beneficially owns 425,000 shares indirectly.
• Greyt Ventures, LLC is owned by a trust for which Ms. Grey serves as trustee.

Sentiment

Score: 7

Explanation: The grant of restricted shares to a director and significant owner is generally a positive sign of alignment and commitment, though it represents a standard compensation practice rather than a significant operational or financial event.

Positives

• The grant of restricted shares to a director and 10% owner aligns management and significant shareholder interests with long-term company performance.
• The equity incentive plan encourages retention and motivation of key personnel.

Negatives

• The grant of shares at a $0 price could be seen as dilutive to existing shareholders, although it is a common practice for equity compensation.

Future Outlook

The vesting schedule for the restricted shares indicates a future commitment from the director, aligning her interests with the company's performance over the next year.

Industry Context

Equity grants to directors and significant owners are a standard practice across industries to incentivize long-term commitment and align interests with shareholders. This is particularly common in growth-oriented companies or those seeking to retain key talent.

Comparison to Industry Standards

• The grant of restricted stock to a director is a common form of executive and director compensation, comparable to practices at companies like Moderna (MRNA) or Tesla (TSLA) which frequently use equity to incentivize leadership.
• A vesting schedule of 8 to 12 months is relatively short compared to typical multi-year vesting schedules (e.g., 3-4 years) often seen for broader employee equity plans, but can be common for director grants or specific retention incentives.

Corporate Governance

Related Party Transactions

• The shares were issued to Greyt Ventures, LLC, which is owned by a trust for which Ms. Grey (the reporting person and director) is trustee, indicating an indirect beneficial ownership structure.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares, but also increased alignment of a significant owner's interests with long-term company performance.
• Management/Directors: The grant serves as compensation and an incentive for the director to contribute to the company's success.

Next Steps

• 50% of the granted restricted shares will vest on the 8th month anniversary of the grant date (approximately September 14, 2026).
• The remaining 50% of the granted restricted shares will vest on the 12th month anniversary of the grant date (approximately January 14, 2027).

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director and significant owner, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Zeo ScientifiX, Inc. While it shows continued alignment of interests, it's not a catalyst for a "buy" or "sell" recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Zeo ScientifiX, ZEOX, Wendy Grey, Greyt Ventures, SEC Form 4, Beneficial Ownership, Restricted Stock, Equity Incentive Plan, Director Compensation, Insider Transaction